Impact Factor and Immediacy Index Rise for Clinical Chemistry from Journal of AACC, Reflecting Journal’s Groundbreaking COVID-19 Research


WASHINGTON, July 1, 2021 / PRNewswire / – The AACC, a global scientific and medical professional organization dedicated to improving health through laboratory medicine, is pleased to announce that the impact factor and immediacy index of its journal Clinical chemistry increased to 8.327 and 8.729, respectively, in the 2020 Clarivate Analytics Journal Citation Reports. These rankings reaffirm that Clinical chemistry is the leading journal on medical laboratory technology – a position she has held for years – and talks about the impact the journal’s science has had on patient care, particularly during the COVID-19 pandemic .

(PRNewsfoto / AACC)

Laboratory medicine is essential to high quality health care and quality of life, which has never been more evident than in the past year and a half as the world grapples with COVID -19. Throughout the pandemic, clinical laboratory testing has played and continues to play a central role in managing the spread of the virus. And as the leading international journal of laboratory medicine, Clinical chemistry is committed to advancing coronavirus testing by highlighting innovative research at the forefront of the field. The journal has also continued to publish peer-reviewed articles advancing the full range of clinical trials for conditions ranging from diabetes to cancer to heart disease. These articles are selected on the basis of the novelty of their discoveries as well as the rigor of the scientific work they detail.

Clinical chemistry the impact factor and the immediacy index testify to the significant influence of the journal, as well as the relevance and timeliness of the research it publishes. The impact factor of a journal is determined by the number of times articles published in the journal are cited over a two-year period, while the immediacy index is determined by the citations of the journal during of a single calendar year. Both are calculated by Clarivate Analytics, a recognized authority for evaluating the usefulness of a journal.

“We at AACC are delighted to see Clinical chemistry the impact factor and the immediacy index go up, ”said AACC CEO Mark J. Golden. “This is a sign that the journal is succeeding in its mission to provide clinical laboratory professionals with the vital scientific information they need to fight COVID-19 and continue to solve other patient health issues. “

About AACC
Dedicated to improving health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, researchers and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, laboratory management and other areas of advancement in laboratory science. Since 1948, the AACC has strived to advance common interests in the field, delivering programs that advance scientific collaboration, knowledge, expertise and innovation. For more information visit www.aacc.org.

Clinical chemistry (clinchem.org) is the leading international journal of laboratory medicine, presenting nearly 400 peer-reviewed studies annually that help patients get accurate diagnoses and essential care. This vital research advances areas of health ranging from genetic testing and drug monitoring to pediatrics and the appropriate use of tests.

Christine DeLong
AACC
Senior Director, Communications and Public Relations
(p) 202.835.8722
[email protected]

Molly polen
AACC
Senior Director, Communications and Public Relations
(p) 202.420.7612
(c) 703.598.0472
[email protected]

Cision

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-impact-factor-and-immediacy-index-rise-for-aaccs-journal-clinical-chemistry-reflecting-the-journals-groundbreaking-covid-19- search-301324561.html

SOURCE AACC


About Hector Hedgepeth

Check Also

Oxford BioDynamics Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for …

Leave a Reply

Your email address will not be published.